Is Rapport Therapeutics, Inc. profitable?

Rapport Therapeutics, Inc. is not currently profitable: it reported a net loss of $107.3M over the trailing twelve months.

What is Rapport Therapeutics, Inc.'s earnings per share?

Rapport Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-2.59.

Where does Rapport Therapeutics, Inc.'s income statement data come from?

Every line is extracted from Rapport Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Rapport Therapeutics, Inc. RAPP Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Total revenue	$20M—	——	——	——	$0—
Research and development	$32.72M+8.1%	$30.26M+35.8%	$22.28M-1.8%	$22.68M+15.9%	$19.57M+13.8%
Selling, general and administrative	$11.5M—	——	——	——	$7.54M—
Total operating expenses	$44.22M+14.8%	$38.51M+28.4%	$29.99M+1.7%	$29.5M+8.8%	$27.11M+15.3%
Operating income	-$24.22M+37.1%	-$38.51M-28.4%	-$29.99M-1.7%	-$29.5M-8.8%	-$27.11M-15.3%
Operating margin	-121.1%—	——	——	——	——
Other income (expense), net	$4.36M-8.2%	$4.75M+55.0%	$3.06M+10.7%	$2.76M-9.2%	$3.05M-14.0%
Net income	-$19.86M+41.2%	-$33.76M-25.4%	-$26.93M-0.7%	-$26.73M-11.1%	-$24.06M-20.4%
Net margin	-99.3%—	——	——	——	——
Diluted earnings per share	-$0.42+40.8%	-$0.710.0%	-$0.71+5.3%	-$0.75-10.3%	-$0.68-467%
EBITDA	-$23.99M+37.3%	-$38.24M-28.6%	-$29.73M-1.7%	-$29.24M-8.9%	-$26.86M-15.5%
EBITDA margin	-119.9%—	——	——	——	——
EBIT	-$24.22M+37.1%	-$38.51M-28.4%	-$29.99M-1.7%	-$29.5M-8.8%	-$27.11M-15.3%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Rapport Therapeutics, Inc. profitable?: Rapport Therapeutics, Inc. is not currently profitable: it reported a net loss of $107.3M over the trailing twelve months.
What is Rapport Therapeutics, Inc.'s earnings per share?: Rapport Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-2.59.
Where does Rapport Therapeutics, Inc.'s income statement data come from?: Every line is extracted from Rapport Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.